Novo Nordisk (NVO) Stock; Gains as $50 Medicare Wegovy Access Challenges Pricing
TLDRs;
- NVO stock gained 1.9% as investors weighed broader Medicare access against potential pressure on Wegovy pricing.
- Medicare’s $50 monthly Wegovy copay could expand demand while reducing revenue generated per eligible prescription.
- Wegovy prescriptions continue climbing, with weekly U.S. volume reaching approximately 575,000 across available formulations.
- Eli Lilly remains a formidable rival as Medicare’s program covers competing GLP-1 obesity treatments.
Novo Nordisk (NVO) stock gained 1.85% to close at $45.71 on Tuesday, outperforming the broader market as investors focused on expanding access to its Wegovy obesity treatment through a new Medicare program. The move came even as pricing pressure remains a central concern for the Danish drugmaker.
The shares advanced while the S&P 500 declined 0.69%, giving Novo Nordisk a notable relative performance advantage during the session. However, the company’s Copenhagen-listed B shares moved in the opposite direction on Wednesday, trading around DKK 293.80 by 09:02 CEST, down 0.86%.
… Continue reading the full article at the original source below.
This content is automatically aggregated. Full credit goes to the original publisher (coincentral.com).
